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iabetes was originally identiﬁed by
thepresenceofglucoseintheurine.
Almost 2,500 years ago it was
noticed that ants were attracted to the
u r i n eo fs o m ei n d i v i d u a l s .I nt h e1 8 t h
and19thcenturiesthesweettasteofurine
was used for diagnosis before chemical
methods became available to detect sugars
intheurine.Teststomeasureglucoseinthe
blood were developed over 100 years ago,
and hyperglycemia subsequently became
the sole criterion recommended for the
diagnosis of diabetes. Initial diagnostic
criteria relied on the response to an oral
glucose challenge, while later measure-
ment of blood glucose in an individual
who was fasting also became acceptable.
The most widely accepted glucose-based
criteria for diagnosis are fasting plasma
glucose (FPG) $126 mg/dL or a 2-h
plasma glucose $200 mg/dL during an
oral glucose tolerance test (OGTT) on
morethanoneoccasion(1,2).Inapatient
with classic symptoms of diabetes, a sin-
gle random plasma glucose $200 mg/dL
is considered diagnostic (1). Before 2010
virtually all diabetes societies recom-
mended blood glucose analysis as the
exclusive method to diagnose diabetes.
Notwithstanding these guidelines, over
the last few years many physicians have
been using hemoglobin A1C to screen for
and diagnose diabetes (3). Although con-
sidered the “gold standard” for diagnosis,
measurement of glucose in the blood is
subject to several limitations, many of
which are not widely appreciated. Mea-
surement of A1C for diagnosis is appeal-
ing but has some inherent limitations.
Theseissueshavebecomethefocusofcon-
siderable attention with the recent publi-
cation of the Report of the International
Expert Committee that recommended
the use of A1C for diagnosis of diabetes
(4), a position that has been endorsed
(at the time of writing) by the American
Diabetes Association (ADA) (1), the En-
docrine Society, and in a more limited
fashionbyAmericanAssociationofClin-
ical Endocrinologists/American College
of Endocrinology (5). This review will
provide an overview of the factors that
inﬂuence glucose and A1C testing.
FACTORS CONTRIBUTING TO
VARIATION IN RESULTS—Before
addressing glucose and A1C, it is impor-
tanttoconsiderthefactorsthatimpactthe
resultsofanybloodtest.Whilelaboratory
medicine journals have devoted some
discussion to the sources of variability in
results of blood tests, this topic has
received little attention in the clinical
literature. Factors that contribute to var-
iation can conveniently be divided into
three categories, namely biological, pre-
analytical, and analytical. Biological vari-
ation comprises both differences within
a single person (termed intraindividual)
and between two or more people (termed
interindividual). Preanalytical issues per-
taintothespecimenbeforeitismeasured.
Analytical differences result from the
measurement procedure itself. The in-
ﬂuence of these factors on both glucose
andA1Cresultswillbeaddressedinmore
detail below.
GLUCOSE MEASUREMENT
FPG
Measurement of glucose in plasma of
fasting subjects is widely accepted as a
diagnostic criterion for diabetes (1,2). Ad-
vantages include inexpensive assays on
automated instruments that are available
in most laboratories worldwide (Table 1).
Nevertheless, FPG is subject to some lim-
itations. One report that analyzed re-
peated measurements from 685 fasting
participants without diagnosed diabetes
from the Third National Health and Nu-
trition Examination Survey (NHANES III)
revealed that only 70.4% of people with
FPG$126mg/dLontheﬁrsttesthadFPG
$126 mg/dL when analysis was repeated
;2weekslater(6).Numerousfactorsmay
contribute to this lack of reproducibility.
These are elaborated below.
Biological variation. Fasting glucose
concentrations vary considerably both
in a single person from day to day and
also between different subjects. Intraindi-
vidual variation in a healthy person is
reported to be 5.7–8.3%, whereas inter-
individual variation of up to 12.5% has
been observed (6,7). Based on a CV (co-
efﬁcient of variation) of 5.7%, FPG can
range from 112–1 4 0m g / d Li na ni n d i -
vidual with an FPG of 126 mg/dL. (It is
important to realize that these values en-
compass the 95% conﬁdence interval,
and 5% of values will be outside this
range.)
Preanalytical variation. Numerous fac-
tors that occur before a sample is mea-
sured can inﬂuence results of blood tests.
Examples include medications, venous
stasis, posture, and sample handling.
The concentrationof glucose in theblood
can be altered by food ingestion, pro-
longed fasting, or exercise (8). It is also
important that measurements are per-
formed in subjects in the absence of
intercurrent illness, which frequently
produces transient hyperglycemia (9).
Similarly, acute stress (e.g., not being
able to ﬁnd parking or having to wait)
can alter blood glucose concentrations.
Samples for fasting glucose analysis
should be drawn after an overnight fast
(no caloric ingestion for at least 8 h),
during which time the subject may con-
sume water ad lib (10). The requirement
that the subject be fasting is a consider-
ablepracticalproblemaspatientsareusu-
allynotfasting whentheyvisitthedoctor,
and it is often inconvenient to return for
phlebotomy. For example, at an HMO af-
ﬁliated with an academic medical center,
69% (5,752 of 8,286) of eligible partici-
pants were screened for diabetes (11).
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REVIEWHowever,FPGwasperformedononly3%
(152) of these individuals. Ninety-ﬁve
percent (5,452) of participants were
screened by random plasma glucose
measurements, a technique not consis-
tent with ADA recommendations. In ad-
dition, blood drawn in the morning as
FPG has a diurnal variation. Analysis of
12,882participantsaged20yearsorolder
in NHANES III who had no previously
diagnosed diabetes revealed that mean
FPG in the morning was considerably
higher than in the afternoon (12). Preva-
lence of diabetes (FPG $126 mg/dL) in
afternoon-examined patients was half
that of participants examined in the
morning. Other patient-related factors
that can inﬂuence the results include
food ingestion when supposed to be fast-
ing and hypocaloric diet for a week or
more prior to testing.
Glucose concentrations decrease in
t h et e s tt u b eb y5 –7 %p e rh o u rd u et o
glycolysis (13). Therefore, a sample
with a true blood glucose value of 126
mg/dL would have a glucose concentra-
tion of ;110 mg/dL after 2 h at room
temperature. Samples with increased
concentrations of erythrocytes, white
blood cells, or platelets have even greater
ratesofglycolysis.Acommonmisconcep-
tion is that sodium ﬂuoride, an inhibitor
of glycolysis, prevents glucose consump-
tion. While ﬂuoride does attenuate in
vitro glycolysis, it has no effect on the
rate of decline in glucose concentrations
intheﬁrst1to2hafter bloodiscollected,
and glycolysis continues for up to 4 h in
samples containing ﬂuoride (14). The de-
lay intheglucosestabilizingeffectofﬂuo-
ride is most likely the result of glucose
metabolism proximal to the ﬂuoride tar-
get enolase (15). After 4 h, ﬂuoride
maintains a stable glucose concentration
for 72 h at room temperature (14). A re-
centpublicationshowedthatacidiﬁcation
of the blood sample inhibits glycolysis in
the ﬁrst 2 h after phlebotomy (16), but the
collection tubes used in that study are not
commercially available. Placing tubes in
ice water immediately after collection may
be the best method to stabilize glucose ini-
tially (2,16), but thisisnot a practicalsolu-
tion in most clinical situations. Separating
cells from plasma within minutes is also
effective, but impractical.
The nature of the specimen analyzed
can have a large inﬂuence on the glucose
concentration. Glucose can be measured
in whole blood, serum, or plasma, but
plasma is recommended by both the ADA
and World Health Organization (WHO)
for diagnosis (1,2). However, many labo-
ratories measure glucose in serum, and
these values may differ from those in
plasma. There is a lack of consensus in the
published literature, with glucose concen-
trations in plasma reported to be lower
than (17), higher than (16,18,19), or the
same as (20) those in serum. Importantly,
glucose concentrations in whole blood are
11% lower than those in plasma because
erythrocytes have a lower water content
than plasma (13). The magnitude of the dif-
ferenceinglucosebetweenwholebloodand
plasma changes with hematocrit. Most de-
vices (usually handheld meters) that mea-
sure glucose in capillary blood use whole
blood. While the majority of these report a
plasma equivalent glucose value (21), this
result is not accurate in patients with ane-
mia (22) (unless the meter measures he-
matocrit).
The source of the blood is another
variable. Although not a substantial prob-
lem in the fasting state, capillary glucose
concentrations can be 20–25% higher
(mean of 30 mg/dL) than venous glucose
during an OGTT (23). This ﬁnding has
practical implications for the OGTT, par-
ticularly because the WHO deems capil-
lary blood samples acceptable for the
diagnosis of diabetes (2).
Analytical variation. Glucose is mea-
sured in central laboratories almost
exclusively using enzymatic methods,
predominantly with glucose oxidase or
hexokinase (24). The following terms are
important for understanding measure-
ment:accuracyindicateshowcloseasingle
measurement is to the “true value” and
precision (or repeatability) refers to the
closeness of agreement of repeated mea-
surementsunderthesameconditions.Pre-
cisionisusuallyexpressedasCV;methods
with low CV have high precision. Numer-
ous improvements in glucose measurement
have produced low within-laboratory
imprecision (CV ,2.5%). Thus, the ana-
lytical variability is considerably less than
the biological variability, which is up to
8.3%. Nevertheless, accuracy of mea-
surement remains a problem. There is
no program to standardize results among
different instrumentsanddifferent labora-
tories. Bias (deviation of the result from
thetruevalue)andvariationamongdiffer-
ent lots of calibrators can reduce the accu-
racy of glucose results. (A calibrator is a
material of known concentration that is
used to adjust a measurement procedure.)
A comparison of serum glucose measure-
ments (target value 98.5 mg/dL) was per-
formed among ;6,000 laboratories using
32 different instruments (25). Analysis
revealed statistically signiﬁcant differ-
ences in bias among clinical laboratory
instruments, with biases ranging from
26to17mg/dL(26to17%)ataglucose
concentration of 100 mg/dL. These con-
siderable differences among laboratories
canresultinthepotentialmisclassiﬁcation
of.12%ofpatients(4).Similarly,inspec-
tion of a College of American Pathologists
(CAP) survey comprising .5,000 labora-
tories revealed that one-third of the time
the results among instruments for an
individual measurement could range be-
tween 141 and 162 mg/dL (26). This var-
iation of 6.9% above or below the mean
reveals that one-third of the time the glu-
cose results on a single patient sample
measured in two different laboratories
could differ by 14%.
OGTT
T h eO G T Te v a l u a t e st h ee f ﬁciency of the
body to metabolize glucose and for many
yearshasbeenusedasthe“goldstandard”
for diagnosis of diabetes. An increase in
postprandial glucose concentration usu-
ally occurs before fasting glucose in-
creases. Therefore, postprandial glucose
is a sensitive indicator of the risk for de-
veloping diabetes and an early marker of
impaired glucose homeostasis (Table 2).
Published evidence suggests that an in-
creased 2-h plasma glucose during an
OGTTisabetterpredictorofbothall-cause
Table 1—FPG for the diagnosis of diabetes
Advantages
c Glucose assay easily automated
c Widely available
c Inexpensive
c Single sample
Disadvantages
c Patient must fast $8h
c Large biological variability
c Diurnal variation
c Sample not stable
c Numerous factors alter glucose
concentrations, e.g., stress, acute illness
c No harmonization of glucose testing
c Concentration varies with source of the
sample (venous, capillary, or arterial
blood)
c Concentration in whole blood is different
from that in plasma
c Guidelines recommend plasma, but many
laboratories measure serum glucose
c FPG less tightly linked to diabetes
complications (than A1C)
c Reﬂects glucose homeostasis at a single
point in time
care.diabetesjournals.org DIABETES CARE, VOLUME 34, FEBRUARY 2011 519
Sacksmortality and cardiovascular mortality or
morbidity than the FPG (27,28). The
OGTT is accepted as a diagnostic modal-
ity by the ADA, WHO/International Di-
abetes Federation (IDF) (1,2), and other
organizations. However, extensive pa-
tient preparation is necessary to perform
an OGTT. Important conditions include,
among others, ingestion of at least 150 g
ofdietarycarbohydrateperdayfor3days
prior to the test, a 10- to 16-h fast,
and commencement of the test between
7:00 A.M. and 9:00 A.M. (24). In addition,
numerous conditions other than diabetes
can inﬂuence the OGTT (24). Consistent
with this, published evidence reveals a
high degree of intraindividual variability
in the OGTT, with a CV of 16.7%, which
is considerably greater than the variabil-
ity for FPG (6). These factors result in
poor reproducibility of the OGTT, which
has been documented in multiple studies
(29,30). The lack of reproducibility, in-
convenience, and cost of the OGTT led
the ADA to recommend that FPG should
bethepreferredglucose-baseddiagnostic
test (1). Note that glucose measurement
in the OGTT is also subject to all the lim-
itations described for FPG (Table 1).
A1C MEASUREMENT—A1C is
formed by the nonenzymatic attachment
of glucose to the N-terminal valine of the
b-chainofhemoglobin(24).Thelifespan
of erythrocytes is ;120 days, and conse-
quently A1C reﬂects long-term glycemic
exposure, representing the average glu-
cose concentration over the preceding
8–12 weeks (31,32). Both observational
studies (33) and controlled clinical trials
(34,35) demonstrate strong correlation
between A1C and retinopathy, as well as
other microvascular complications of di-
abetes. More importantly, the A1C value
predictsthe risk of microvascularcompli-
cations and lowering A1C concentrations
(by tight glycemic control) signiﬁcantly
reduces the rate of progression of micro-
vascular complications (34,35).
Biological variation. Intraindividualvar-
iation of A1C in nondiabetic people is
minimal (36) (Table 3), with CV ,1%
(37). Variability between individuals is
greater. Data derived from several inves-
tigators implythatA1Cvalues maynotbe
constant among all individuals despite
the presence of similar blood glucose or
fructosamine concentrations (38). Some
investigatorshavetermedthisa“glycation
gap” and proposed that there are differ-
ences in the rate of glycation of hemo-
globin (“low and high glycators”) (39).
Studies of twins with type 1 diabetes
support a genetic contribution to A1C
values (40), and heritability of the glyca-
tion gap was observed in healthy female
twins (41). However, the glycation gap is
essentially a measure of A1C adjusted for
fructosamine. Importantly, measurement
of fructosamine, which is glycated albu-
min and protein, suffers from several lim-
itations (42). In addition, some authors
have questioned the statistical analysis
(which is not standard) used in deter-
mining the glycation gap and noted the
statistical tautology that the outcome is
correlated with the residual from a regres-
sion (43). Importantly, the postulate of a
glycation gap remains unsubstantiated by
data because glycation rates cannot be
measured accurately in vivo. In addition,
the hemoglobin glycation index (differ-
ence between observed A1C and that pre-
dicted from blood glucose) is not an
independent predictor of the risk of mi-
crovascular complications (43), and the
possible clinical signiﬁcance of the glyca-
tion gap is unclear.
Accumulating evidence supports the
hypothesis that race inﬂuences A1C.
Initial studies in patients with diabetes
reported statistically signiﬁcant differ-
ences in A1C concentrations among races
(44). While adjusted for factors that may
inﬂuence glycemia, it remains possible
that these differences may be due to var-
iationsinglycemiccontrol.Morecompel-
lingsupportwasprovidedinNHANESIII
whereMexicanAmericansandblackshad
higher average A1C values than whites
(45,46). Similar ﬁndings were observed
in adults with impaired glucose tolerance
in the Diabetes Prevention Program (47)
and validated in a cross-sectional analysis
of two studies (48). Collectively these
data suggest that there are differences in
A1C concentrations among racial groups.
However, it isnotclear that these changes
have clinical signiﬁcance. A1C was mea-
sured in the Atherosclerosis Risk in Com-
munities (ARIC) study in 11,092 adults
who did not have a history of diabetes
or cardiovascular disease (49). Consistent
with prior publications, blacks had mean
A1C values 0.4% higher than whites.
Nevertheless, race did not modify the as-
sociation between the A1C value and ad-
verse cardiovascular outcomes and death
(49). Because follow-up revealed that
blacks with biochemically deﬁned inci-
dent diabetes were signiﬁcantly less likely
than whites to report having received a
diagnosis of diabetes by a physician, the
authors speculate that delays in diagnosis
may explain the higher A1C values in
blacks.
The molecular mechanism underly-
ing the racial and ethnic differences
remains to be established. Possibilities
include differences in rates of glucose
uptake into erythrocytes, rates of intra-
erythrocytic glucose metabolism, rates of
glucose attachment to or release from
hemoglobin or erythrocyte life span
(50,51). Regardless of the mechanism,
the variations in A1C concentrations are
Table 2—OGTT for the diagnosis of
diabetes
Advantages
c Sensitive indicator of risk of developing
diabetes
c Early marker of impaired glucose
homeostasis
Disadvantages
c Lacks reproducibility
c Extensive patient preparation
c Time-consuming and inconvenient for
patients
c Unpalatable
c Expensive
c Inﬂuenced by numerous medications
c Subject to the same limitations as FPG,
namely, sample not stable, needs to be
performed in the morning, etc.
Table 3—A1C for the diagnosis of diabetes
Advantages
c Subject need not be fasting
c Samples may be obtained any time of the
day
c Very little biological variability
c Sample stable
c Not altered by acute factors, e.g., stress,
exercise
c Reﬂects long-term blood glucose
concentration
c Assay standardized across instruments
c Accuracy of the test is monitored
c Single sample, namely whole blood
c Concentration predicts the development
ofmicrovascularcomplicationsofdiabetes
c Used to guide treatment
Disadvantages
c May be altered by factors other than
glucose, e.g., change in erythrocyte life
span, ethnicity
c Some conditions interfere with
measurement, e.g., selected
hemoglobinopathies
c May not be available in some laboratories/
areas of the world
c Cost
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A1C versus glucose testingrelatively small (#0.4%), and no consen-
sus has been reached on whether different
cutoffs should be used for different races.
Preanalytical variation. Most factors
that alter FPG do not signiﬁcantly affect
A1C concentrations. Acute illness, short-
term lifestyle changes (e.g., exercise),
recent food ingestion, and sample han-
dlingdonotsigniﬁcantlyalterA1Cvalues
(Table 3). Importantly, whole blood sam-
ples are stable for 1 week at 4°C and for at
least 1 year at 270°C or colder (13,52).
The interpretation of A1C depends
on the erythrocytes having a normal life
span. Patients with hemolytic disease or
other conditions with shortened erythro-
cyte survival have a substantial reduction
in A1C (53). Similarly, individuals with
acute blood loss have spuriously low
A1C values because of an increased frac-
tion of young erythrocytes. False in-
creases in A1C have been reported with
some methods in patients with hypertri-
glyceridemia, hyperbilirubinemia, ure-
mia, chronic alcoholism, or chronic
ingestion of salicylates (13). Because
most interferences are method speciﬁc,
in many cases they can be overcome by
selecting an appropriate method that is
not subject to the interference.
Individuals with iron deﬁciency ane-
miahaveincreasedA1Candfructosamine
concentrations(54),bothof whicharere-
duced by therapy with iron (54,55). A
mechanism for the higher A1C was re-
cently identiﬁed by the demonstration
that malondialdehyde, which is increased
in subjects with iron deﬁciency anemia
(54), augments glycation of hemoglobin
(56). However, the magnitude of the
increase in A1C is probably small. Exam-
ination of 10,535 adults without self-
reporteddiabetesinNHANESIIIrevealed
that while 13.7% of women had iron de-
ﬁciency, only 4.74% and 0.48% had A1C
$5.5% or $6.5%, respectively (57). Iron
deﬁciency in women was associated
with a small (odds ratio 1.39) yet signiﬁ-
cant greater odds of A1C $5.5% but not
with greater odds of A1C $6.5%. Iron
deﬁciency was rare in men (,0.5%)
(57). Nevertheless, it would seem pru-
dent to correct the iron deﬁciency before
measuring A1C in individualswith severe
iron deﬁciency anemia.
Analytical variation. There are ;100
different methods used to measure A1C.
The most widely used commercial meth-
odsuseeitherantibodies(immunoassays)
or cation-exchange chromatography (most
commonly high-performance liquid chro-
matography) to separate the glycated
(A1C) from the nonglycated hemoglobin
(24).TheNationalGlycohemoglobinStan-
dardization Program (NGSP) has been in-
strumental in standardizing A1C testing
among laboratories (58,59), particularly
(but not exclusively) in the U.S. The
NGSP has markedly improved the perfor-
mance of A1C testing (58). At the time of
writing, the vast majority (93%) of clinical
laboratories that participate in CAP surveys
use methods with between-laboratory CVs
,5% (www.ngsp.org). Within laboratory
CVs for some methods are as low as
,0.5%.Inaddition,theInternational Fed-
eration for Clinical Chemistry (IFCC)
developed a reference method using mass
spectrometry (or capillary electrophoresis)
forA1Cmeasurement,whichshouldresult
in international harmonization as it facili-
tates traceability to a metrologically sound
accuracy base.Itisimportant to emphasize
that the IFCC method is technically com-
plex,timeconsuming,andexpensiveandis
not designed for routine analysis of patient
samples.
HemoglobinvariantsaffectsomeA1C
measurements. The most common var-
iants are HbS, HbE, HbC, and HbD. A1C
measurement is not appropriate in sub-
jects homozygous for HbS or HbC, with
HbSC or with any other variant that alters
erythrocyte survival. However, A1C can
be measured accurately in individuals
heterozygous for HbS, HbE, HbC, or
HbD and in those with increased HbF,
provided an appropriate assay is used
(53,60). Only ;4% of the 3,378 clinical
laboratories that participated in the 2010
GH2 College of American Pathologists
survey (which measures A1C) use meth-
odsinwhichHbASorHbAChasclinically
signiﬁcant interference. In addition, if the
sample is analyzed by high-performance
liquid chromatography method, careful
inspection of the chromatogram usually
reveals the aberrant peaks produced by
the variant hemoglobin. The presence
of a hemoglobin variant should be con-
sidered if A1C is .15% or if a large
change in A1C coincides with a change
in laboratory A1C method (53). In these
situations, hemoglobin electrophore-
sis should be performed. It is important
to emphasize that, like any other test,
A1C results that are inconsistent with
the clinical presentation should be inves-
tigated.
PERSPECTIVE—Notwithstandingthe
use of glucose (FPG and/or the OGTT) as
the “gold standard” for the diagnosis of
diabetes for many years, glucose testing
suffers from several deﬁciencies. The
r e q u i r e m e n tt h a tt h es u b j e c tb ef a s t i n g
at the time the blood is drawn is a con-
siderable inconvenience. While our abil-
ity to measure glucose has improved,
inherent biological variability can pro-
duce very large differences within and
among individuals. In conjunction with
lack of sample stability, which is difﬁcult
to overcome in clinicalpractice, these fac-
tors results in lack of reproducibility of
glucose testing.
A1C, which reﬂects chronic blood
glucose values, is routinely used in mon-
itoring glycemic control and guiding
therapy. The signiﬁcant reduction in
microvascular complications with lower
A1C and the absence of sample lability,
combined with several other advantages
(Table 3), have led to the recommenda-
tion by some organizations that A1C be
usedforscreeninganddiagnosisofdiabe-
tes (1). Accumulating evidence suggests
that racial differences in A1C values may
be present, and the possible clinical sig-
niﬁcance of this needs to be determined.
Importantly, A1C cannot be measured in
certain conditions. Despite these caveats,
A1C can be measured accurately in the
vastmajority ofpeople.Acomprehension
of the factors that inﬂuence A1C values
and the conditions where it should not
be used will produce accurate and clini-
cally meaningful results. The convenience
of sampling at any time without regard to
foodingestionmakesitlikelythatmeasure-
ment of A1C will result in the detection of
many of the millions of people with diabe-
tes who are currently undiagnosed.
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